


Remarks

The specification has been amended to correct the inadvertent typographical errors. With respect to the amendment made to page 25, SEQ ID NOS: 7 and 8 have been replaced with SEQ ID NOS: 5 and 6, respectively, as the latter SEQ ID NOS: are the only two oligonucleotide primers set forth in the instant Sequence Listing. The incorrectly recited SEQ ID NOS: 7 and 8 are directed to the cDNA and the full-length amino acid sequence for the human long extracellular form of B7L-1, respectively. Since they cannot be used for the PCR cloning as described in Example 7, it must have been an inadvertent error. With respect to the amendment made to page 27, the term B7L-1 was replaced with LDCAM, where appropriate, to maintain the consistency that LDCAM is the antigen, as described in the first, non-amended paragraph of Example 10. The applicants thus believe that these amendments do not introduce any new matters.

Respectfully submitted,



Paul B. Tran, Ph.D.
Attorney/Agent for Applicants
Registration No.: 41,565
Phone: (805) 447-9768
Date: April 7, 2004

Please send all future correspondence to:

US Patent Operations/ PBT
Dept. 4300, M/S 27-4-A
AMGEN INC.
One Amgen Center Drive
Thousand Oaks, California 91320-1799